ZB India Sales Intelligence
Comprehensive Analysis Report

ROM leads in entries (21), followed by South (18), East and UNR (7 each). Delhi and Mumbai are under-represented (3 each) relative to their commercial potential — a coverage gap that should be investigated.

Nearly every sales rep identifies both market share and knee implant revenue as live problems. This co-occurrence (72% of entries cite both) indicates these are not separate issues — they are one compound problem: ZB is losing volume to Stryker (MAKO) and DePuy across private and corporate chains simultaneously.

The dominant ROSA problem is narrative leadership, not hardware. ZB has the robot in the field but the brand story is not being told persuasively at the hospital board and surgeon level. 44 entries flag this — it is the highest-frequency ROSA signal. The implant pull-through gap (15 entries) is especially high-value since each ROSA case should drive implant revenue; this conversion is failing at 23% of accounts.

70% of entries show no activated KOL champion. This is a systemic gap — ZB's route to the hospital decision-maker runs through the surgeon champion, and that champion is absent in most accounts. Without this, both ROSA utilisation and preferred vendor negotiations stall.

Half the entries (33/66) identify team misalignment between Implant and ROSA. This is an organisational design problem, not a motivation problem. The two teams are operating as separate cost centres competing for the same account. Competition objection handling (28 entries) points to a specific skills gap: reps are being challenged on the ROSA vs. MAKO (90-landmark vs. 36-landmark) narrative and are not winning those conversations.

The top 3 priorities (Unified Revenue Engine, Bundled Pricing, KOL Ecosystem) are nearly equally cited — this represents a clear field consensus. Management should treat all three as simultaneous Workstream 1 priorities, not sequenced.

47 of 66 entries (71%) identify new ROSA placement as the primary revenue lever — the field is primarily in new-business acquisition mode for ROSA. However, already-installed robots are underutilised (9 accounts flagged). Management must run a dual strategy: (a) accelerate new placements, (b) simultaneously drive utilisation at installed sites via ROSA Optimize.

Corporate chain accounts (Apollo, Max, Fortis, Manipal) represent 28 of 66 entries — 42% of field attention. The dominant play: patient awareness campaigns co-created with hospital marketing, combined with a preferred vendor contract. This is a partnership model, not a transactional one — and requires CMO/CEO-level sponsorship, not just procurement.

Surgeon onboarding and Tier-2 city expansion are equally prioritised (42 each). Tier-2 expansion is especially significant for ROSA since competition has not yet established a Tier-2 robotic presence in most markets. Government tendering is virtually absent from the field agenda (3 entries).

The field is primarily targeting surgeons and HODs (clinical layer), but 88% of entries also identify the CMO/Medical Director relationship as a problem — meaning the field has the aspiration to reach institutional decision-makers but lacks the relationship, tools, and seniority support to do so. This is the Institutional Selling Skills gap (27 entries) in action.